Major Indian hospital stocks recorded advances of up to 5% on a Friday trading session despite new government restrictions on oncology drug markups. The federal policy imposes a 30% limit on trade margins for non-scheduled anti-cancer medications, extending earlier margin restrictions that applied solely to selected oncology drugs. Authorities introduced the rule to control excessive supply chain markups, make oncology care affordable, and maintain product availability.
The regulatory intervention could lower prices for various cancer drugs by up to 70%, generating estimated annual patient savings of Rs 2,500 crore. In stock market trading, Fortis Healthcare climbed over 5% to reach Rs 805 per share, while Max Health rose over 4% to Rs 915. Apollo Hospitals, Manipal, Medanta, and Dr Agarwal's experienced gains of 4%, 3.5%, 3.1%, and 2% respectively.
Analyst commentaries indicate that financial disruptions across the sector may remain constrained over the long term. Research firm Emkay reported that pharmacies generate 15% to 20% of total hospital revenues with margins ranging between 20% and 25%. Emkay noted that margin limits will chiefly affect self-paying individuals, as patients under public health programs or insurance plans utilize pre-agreed package rates discounted from rack tariffs rather than maximum retail prices.
Investment bank Jefferies stated that short-term operating margins might experience pressure, but historical patterns suggest companies adapt successfully. When authorities reduced cardiac stent and orthopaedic knee implant prices by 70% to 85% nearly ten years ago, healthcare operators offset revenue losses over 12 to 15 months through phased fee adjustments and cost containment. Following the stent and implant price limits in 2017, Apollo Hospitals restored its EBITDA margins within a few quarters.
Regulatory developments have historically depressed hospital equity values for three to six months prior to a rebound. Following the February 2017 stent restrictions and August 2017 implant limits, Apollo Hospitals achieved a 3% return in fiscal year 2018-19. Similarly, share prices initially dropped but rebounded within six months when an NGO filed a public interest litigation in the Supreme Court in February 2024 seeking standardized procedure tariffs.
Beyond oncology drugs, media reports indicate the government has initiated discussions with industry stakeholders regarding trade margin rationalization for medical consumables and devices. Consumables represent 12% to 15% of a typical patient bill, though high-value items have faced price caps since 2017. Analysts project that potential policy actions regarding consumables will produce manageable effects on underlying EBITDA.
Market valuation metrics show hospital equities trading at 21x to 25x FY28E EV/EBITDA, down from 25x to 35x a year prior. While Emkay cited operational hurdles preventing blanket margin caps across all non-scheduled drugs, it noted ongoing regulatory exposure due to the sector's socio-economic sensitivity. Underlying demand for tertiary-care beds remains steady across major hospital networks.
Key numbers
- Non-scheduled oncology drug trade margin cap: 30%
- Maximum potential reduction in cancer drug prices: 70%
- Estimated annual savings for patients: Rs 2,500 crore
- Pharmacy share of overall hospital revenue: 15-20%
- Hospital sector forward valuation range: 21x-25x FY28E EV/EBITDA
What a board might note
- Should the finance team audit the share of revenue derived from pharmacy sales and non-scheduled cancer drugs to evaluate exposure to the 30% trade margin cap?
- How might the hospital adjust procedure fees or cost structures over a 12-to-15 month period to counter margin compression, similar to strategies used following the 2017 price caps on stents and implants?
- What portion of the hospital's patient mix relies on self-payment versus pre-negotiated insurance and public scheme package rates that bypass maximum retail price adjustments?
- How could potential government discussions regarding trade margin limits on medical devices and consumables affect future EBITDA if consumables currently represent 12% to 15% of patient bills?
Source: Economic Times, 9 October 2026. This is a summary of a news report, published as general information. It is not legal, tax or investment advice.
This article is journalism and commentary. It is not a recommendation to buy or sell any security, and it is not professional advice. Read the full disclaimer.
